Abstract 977P
Background
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor globally, Hence, there is an urgent need for safer and more effective options to improve the survival rates of HCC patients. This study aims to evaluate the viability, efficacy, and safety of HAIC and Regorafenib combined with PD-1 inhibitors for treating advanced HCC patients.
Methods
This is a multicenter, randomized controlled clinical study of hepatocellular carcinoma. Eligible individuals with unresectable HCC were randomized into either the HAIC combined with regorafenib and PD-1 inhibitors group (HAIC+REG+ICIs group) or the regorafenib combined with PD-1 inhibitors group (REG+ICIs group). The primary endpoint is the objective response rate (ORR). Secondary endpoints include PFS, OS, DCR (all assessed by BICR per RECIST v1.1), and safety.
Results
Up to April 24, 2023, a total of 45 patients were enrolled and all patients are available for analysis. The HAIC+REG+ICIs group and the REG+ICIs group included 28 and 17 patients, respectively.The median age were 52.5 years (range, 32-68) and 47.0 years (range, 24-79), 92.9% and 94.1% were male for each group, the proportions of child-pugh A/B were 64.3%/35.7% vs. 88.2%/11.8%; and the patients with China Liver Cancer Staging (CNLC) Ib/IIa/IIb/IIIa/IIIb/IV stage were 0.0%/3.6%/35.7%/21.4%/32.1%/7.1% vs. 5.9%/11.8%/47.1%/11.8%/17.6%/5.9%, respectively. All patients were infected with HBV. The median follow-up time was 16.6 months (1-21.2). The ORR was 39.3% (11/28) and 29.4%(5/17) for HAIC+REG+ICIs group and the REG+ICIs group, P=0.502. DCR was 82.1%(23/28) and 52.9%(9/17) respectively, P=0.036. The median OS of HAIC+REG+ICIs group was significant longer than REG+ICIs group (19.1 vs. NA months, P=0.03; HR=0.039 95% CI: 0.101-0.941). This study is currently ongoing.
Conclusions
HAIC combined with Regorafenib and PD-1 inhibitors compared with Regorafenib and PD-1 inhibitors showed a better tumor response rate, but there was no significant difference. However HAIC combined with regorafenib and PD-1 inhibitors can significantly prolong the overall survival of second-line HCC patients.
Clinical trial identification
ChiCTR2100046555.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
842P - Multicenter real-world study of newly diagnosed advanced-stage extranodal natural killer/T cell lymphoma (ENKTL): Proposal for intensive therapy
Presenter: Yu-Ce Wei
Session: Poster session 18
844P - Progression -free survival prediction of multiple myeloma patients in five European countries using machine learning models
Presenter: Maria Luisa Pleguezuelo Witte
Session: Poster session 18
845P - A machine learning based clinical platform for cancer subtyping and data integration in hematological malignancies
Presenter: Michelle Tang
Session: Poster session 18
846P - Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19
Presenter: Souad Assaad
Session: Poster session 18
847P - Fatal infections among leukemia patients
Presenter: Huijie Zhou
Session: Poster session 18
848P - Mortality after rasburicase vs allopurinol anti-hyperuricemia monotherapy in patients with liquid tumors
Presenter: Mitchell Cairo
Session: Poster session 18
849P - Long non-coding RNA signatures and their role in the progression of childhood T cell acute lymphoblastic leukemia
Presenter: Pankaj Sharma
Session: Poster session 18
850P - A zebrafish model of MYC-driven acute myeloid leukemia reveals that neutrophil resistance to oncogenic transformation depends on their ability to promote PP2A-mediated MYC proteasomal degradation
Presenter: Anna Maria Luciano
Session: Poster session 18
851P - Characterization of a zebrafish model of MYC-driven acute myeloid leukemia
Presenter: Anna Maria Luciano
Session: Poster session 18
852P - c-MAF-driven metabolic reprogramming mediates H3K27 hyperacetylation to regulate super enhancer-associated genes
Presenter: Phyllis SY Chong
Session: Poster session 18